Participating Faculty

The American Journal of Managed Care

This supplement to includes information on the burden of illness, costs and comorbidities, and work loss associated with bipolar disorder. This program has been peer reviewed by an expert in the field.

Faculty

Charles L. Bowden, MDProfessor of Psychiatry and Pharmacology

University of Texas Health Science Center at San Antonio

Titus H. Harris Chair

Department of Psychiatry and Behavioral Sciences

Galveston, Texas

Martha Sajatovic, MD

Department of Psychiatry

Cleveland, Ohio

Lana A. Vornik, MSc

Department of Psychiatry and Behavioral Sciences

Galveston, Texas

Faculty Disclosure

The American Journal of Managed Care

It is the policy of to have all faculty who participate in programs sponsored by pharmaceutical companies disclose any real or apparent conflicts of interest.

The following participants report relationships with pharmaceutical companies: Charles L. Bowden, MD

Research Grant From:

• Bristol-Myers Squibb
• National Institute of Mental Health
• R.W. Johnson Pharmaceutical Institute
• Stanley Medical Research Foundation

Speakers

' Bureau For:

• Pfizer

Research Grant From, Consultant To, Speakers

' Bureau For:

• GlaxoSmithKline
• Lilly Research

Consultant To:

• Sanofi-Synthelabo UCB Pharma

Robert M.A. Hirschfeld, MD

Consultant To and and/or Advisory Board For:

• AstraZeneca
• Eli Lilly
• GlaxoSmithKline
• Novartis
• Pfizer
• UCB Pharma Wyeth-Ayerst

Martha Sajatovic, MD

Grant Research Support From:

• Abbott
• Eli Lilly

Consultant To:

• AstraZeneca
• Eli Lilly
• Janssen

Speaker

' s Bureau For:

• Bristol-Myers Squibb
• Janssen Pfizer

The following participant reports no relationships with any pharmaceutical company:

• Lana A. Vornik, MSc

The American Journal of Managed Care,

Signed disclosures are on file at the offices of Jamesburg, New Jersey.

This program is being supported by an educational grant from AstraZeneca.

The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.

Download PDF: Participating Faculty